Berman Capital Advisors’s Cyclerion Therapeutics CYCN Stock Holding History

Berman Capital Advisors’s Portfolio CYCN Stock Details CYCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$2K	Sell	43 -32	-43%	-$2.09K	﹤0.01%	1675
2021 Q2	$5K	Hold	75	–	–	﹤0.01%	1336
2021 Q1	$4K	Sell	75 -1	-1%	-$75	﹤0.01%	1320
2020 Q4	$4K	Buy	+76	New	+$5.18K	﹤0.01%	1206
2020 Q3	–	Hold	0	–	–	–	1627
2020 Q2	–	Hold	0	–	–	–	1644
2020 Q1	–	Hold	0	–	–	–	1506
2019 Q4	–	Hold	0	–	–	–	1476
2019 Q3	–	Hold	0	–	–	–	1467
2019 Q2	–	Hold	0	–	–	–	1490

Other funds holding CYCN

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Berman Capital Advisors's CYCN Position: Q3 2021 in Review

Berman Capital Advisors reduced its Cyclerion Therapeutics (CYCN) stake by 43% in Q3 2021, selling an estimated $2.09K and leaving 43 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #1675.

Berman Capital Advisors first reported a position in CYCN in Q4 2020 and has held it in 4 quarters since. The position peaked at $5K in Q2 2021. 61 funds tracked by Wall St. Rank hold CYCN as of Q3 2021.

Berman Capital Advisors held 43 shares of Cyclerion Therapeutics worth $2K as of Q3 2021.
Berman Capital Advisors sold 32 Cyclerion Therapeutics shares in Q3 2021, an estimated $2.09K.
Cyclerion Therapeutics made up ﹤0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #1675 holding.
Berman Capital Advisors first reported a position in Cyclerion Therapeutics in Q4 2020 and has held it in 4 quarters since.
Berman Capital Advisors's Cyclerion Therapeutics position peaked at $5K in Q2 2021.
61 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.